港股異動丨康希諾生物-B(6185.HK)大漲7.7% 公司申請新冠疫苗在墨西哥的使用授權
格隆匯2月8日丨康希諾生物-B(6185.HK)大漲7.7%,報361港元,盤中高見369港元再創上市以來新高,總市值893億港元;康希諾(688185.SH)亦漲4.26%。墨西哥外長Ebrard上週末表示,康希諾申請疫苗在墨西哥的使用授權,康希諾首針新冠疫苗將在克雷塔羅裝瓶。此外,港交所權益資料顯示,康希諾生物—B(06185-HK)獲摩根大通於02月02日在場內以每股平均價295.3227港元增持34.26萬股,涉資約1.01億港元。增持後,摩根大通的最新持股數目為1224.42萬股,持股比例由8.97%增持至9.22%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.